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AbstrAct
Objectives Low-frequency electrical muscle 
stimulation (LF-EMS) may have the potential to reduce 
breathlessness and increase exercise capacity in the 
chronic heart failure population who struggle to adhere 
to conventional exercise. The study’s aim was to 
establish if a randomised controlled trial of LF-EMS was 
feasible.
Design and setting Double blind (participants, outcome 
assessors), randomised study in a secondary care 
outpatient cardiac rehabilitation programme.
Participants Patients with severe heart failure (New 
York Heart Association class III–IV) having left ventricular 
ejection fraction <40% documented by echocardiography 
were eligible.
Interventions Participants were randomised (remotely 
by computer) to 8 weeks (5×60 mins per week) of 
either LF-EMS intervention (4 Hz, continuous, n=30) 
or sham placebo (skin level stimulation only, n=30) of 
the quadriceps and hamstrings muscles. Participants 
used the LF-EMS straps at home and were supervised 
weekly
Outcome measures Recruitment, adherence and 
tolerability to the intervention were measured during 
the trial as well as physiological outcomes (primary 
outcome: 6 min walk, secondary outcomes: quadriceps 
strength, quality of life and physical activity).
results Sixty of 171 eligible participants (35.08%) 
were recruited to the trial. 12 (20%) of the 60 patients 
(4 LF-EMS and 8 sham) withdrew. Forty-one patients 
(68.3%), adhered to the protocol for at least 70% of 
the sessions. The physiological measures indicated no 
significant differences between groups in 6 min walk 
distance(p=0.13) and quality of life (p=0.55) although 
both outcomes improved more with LF-EMS.
conclusion Patients with severe heart failure can 
be recruited to and tolerate LF-EMS studies. A larger 
randomised controlled trial (RCT) in the advanced heart 
failure population is technically feasible, although 
adherence to follow-up would be challenging. The 
preliminary improvements in exercise capacity 
and quality of life were minimal and this should be 
considered if planning a larger trial.
trial registration number ISRCTN16749049
IntrODuctIOn
Chronic heart failure (CHF) affects approx-
imately 26 million people worldwide1 and is 
associated with a poor prognosis; 30%–40% 
of patients diagnosed with heart failure die 
within a year.2 Patients in New York Heart 
Association (NYHA) class III/IV are unable to 
perform the simplest daily activities, become 
depressed and have a poor quality of life.3
Regular aerobic exercise reduces breathless-
ness and muscle dysfunction for individuals 
with CHF while improving exercise capacity.4–6 
According to the ExTraMATCH meta-anal-
ysis,7 exercise training leads to a 35% relative 
reduction in mortality, similar to the effects of 
beta-blockers8 and angiotensin-converting-en-
zyme inhibitors.9 However, those with advanced 
CHF are often so limited that they are unable to 
gain the holistic benefits of exercise.4 7
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Research
strengths and limitations of this study
 ► To our knowledge, this was the first study to evaluate 
the design of a study into LF-EMS in patients with 
advanced (New York Heart Association class III–IV) 
heart failure.
 ► Analysis of recruitment, retention and adherence 
in this hard to reach group contributes useful 
knowledge to the heart failure literature on 
how practical exercise interventions could be 
implemented.
 ► This study was a real-world feasibility study. Patients 
with advanced heart failure were recruited when 
deemed eligible by experienced clinicians based 
on available information. This approach can be 
subjective and lead to variability in disease severity 
in our sample. However, this is in keeping with the 
pragmatic aim of our trial and provides external 
validity to our findings.
 ► This study had a small sample size and was not 
powered or designed to assess the effects of LF-
EMS in advanced heart failure. The findings should 
therefore be considered preliminary.
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Electrical muscle stimulation (EMS) may provide 
an alternative rehabilitative therapy for this group. In 
patients with mild to moderate CHF, EMS can improve 
muscle strength of the legs, exercise capacity and quality 
of life.10–12 Low-frequency (4–5 Hz) EMS (LF-EMS) 
produces shivering-like subtetanic muscle contractions 
that can stimulate an aerobic response equivalent to 51% 
of maximal oxygen uptake.13 Therapeutic levels of aerobic 
exercise can thus be achieved passively by LF-EMS,14 and 
it has been shown to be comfortable and well tolerated 
in healthy individuals and those with mild to moderate 
CHF.15 16 However, the impact of LF-EMS in patients 
with advanced heart failure (New York Heart Association 
(NYHA) class III/IV) is currently unknown. As patients 
with advanced heart failure have shown poor uptake and 
adherence to intervention studies,17 a preliminary study 
was needed to determine the feasibility of LF-EMS in this 
patient cohort prior to the development of a large-scale 
definitive trial.
Based on recommendations for good practice in the 
design of pilot and feasibility studies,18 this study was 
undertaken with the following aims: to (1) test the robust-
ness of the study protocol for a potential future trial; (2) 
estimate rates of recruitment, consent and retention; (3) 
determine the tolerability of the LF-EMS intervention 
and the effectiveness of the sham placebo in the NYHA 
III/IV CHF population and (4) gain initial estimates of 
the efficacy of LF-EMS for all potential primary outcomes. 
This can be used for sample size calculations in future 
substantive trials.
MethODs
Experimental design
This feasibility study used a double-blind parallel group 
randomised control design. Participants were randomised 
to either LF-EMS or ‘sham’ placebo for a period of 
8 weeks and blinded to group allocation. Outcomes were 
assessed at baseline (prerandomisation), 8 week and 20 
week follow-up.
recruitment and screening
Between October 2013 and March 2015, University 
Hospital Coventry and Warwickshire, (UHCW) Hospital 
NHS Trust heart failure clinics lists were screened for 
patients fulfilling the eligibility criteria for the study. Sixty 
eligible participants were recruited. The study conformed 
to the Declaration of Helsinki and was approved by the 
local NHS Ethics Committee. All participants provided 
written informed consent.
randomisation
The trial statistician, in conjunction with Warwick Clin-
ical Trials Unit, generated the randomisation sequence 
remotely (by computer) using permuted block randomi-
sation. Group allocation was concealed from outcomes 
assessors and participants.
Participants
Male and female adults, >18 years old, with stable CHF, 
documented by echocardiography of left ventricular 
systolic dysfunction (ejection fraction <40%) were 
eligible for the study. All participants had NYHA func-
tional class III–IV symptoms as judged by an experienced 
heart failure cardiologist. Participants were required to 
be medically stable, defined as the absence of hospital 
admission or alterations in medical therapy within the 
preceding 2 weeks. Exclusion criteria for safety and prac-
tical reasons were: (1) presence of implantable cardiac 
devices, (2) serious cardiac arrhythmias,(3) neurolog-
ical disorders or previous stroke significant enough to 
limit exercise, (4) orthopaedic problems that prevented 
walking, (5) neuromuscular disease, (6) dementia or (7) 
a mid-thigh circumference of >50 cm (due to the size of 
the LF-EMS straps).
LF-eMs stimulation
The LF-EMS equipment (Biomedical Research Limited, 
Galway, Ireland) consisted of a pair of neoprene straps 
containing built-in adhesive gel electrodes. The equip-
ment is Conformite Europeene(CE)marked under the 
European Medical Device Directive. The stimulator 
current waveform was designed to produce rhythmical 
contractions in the leg muscle groups occurring at a pulse 
frequency of 4–5 Hz (pulse width: 620 µs). The maximum 
peak output pulse current used was 140 mA.
LF-eMs intervention
Participants used the LF-EMS or sham placebo for 1 hour, 
five times a week, for eight consecutive weeks. Of the 
five hourly sessions per week, four were completed unsuper-
vised in the participant’s own home. The remaining session 
was conducted in a cardiac rehabilitation outpatient setting 
under the supervision of an exercise physiologist. The 
LF-EMS technology was retrospectively interrogated (ie, at 
the weekly supervised sessions) to report date, frequency, 
duration and stimulation intensity.
‘sham’ placebo intervention
In the sham arm of the study, participants were provided 
with identical straps and electrodes. In contrast to the 
LF-EMS group, the controller was programmed to deliver 
a very low level of stimulation (frequency: 99 Hz, pulse 
width: 150 µs, maximum current amplitude: 7.3 mA). 
This provided sensory input to the skin surface but little 
or no muscle activation. Participants in the sham group 
had the same induction, supervision and follow-up as the 
intervention arm.
Outcome measures
Feasibility criteria
In relation to the design of pilot and feasibility studies, 
Thabane et al19 recommend stipulating criteria for success 
‘a priori’. The feasibility criteria were:
1. Recruitment rate: at least 40% of eligible participants 
recruited to the trial.
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2. Retention: no more than 33% of participants drop 
out during the intervention period.
3. Adherence: 66% of participants tolerate the 
intervention and adhere to the protocol for ≥70% of 
the intervention period.
4. Placebo efficacy: participants would be able to guess 
their group allocation no more often than would be 
expected by chance.
Primary outcome
6 min walk test
The 6 min walk test (6MWT) was conducted in accor-
dance with the American Thoracic Society guidelines.20 
Participants were instructed to walk as far as possible in 
6 min along a 30 m, flat, obstacle free corridor, turning 
180° at the end of every 30 m. Standardised instructions 
and verbal encouragement were given.
Secondary outcomes
Isometric muscle strength
A hand-held dynamometer (MicroFET2 Torque/Force 
indicator, Hoggan Health Industries, Utah, USA) vali-
dated for assessing functional leg strength in elderly 
populations was used.21 Participants sat in an elevated 
chair and were instructed to maximally extend the knee 
while the assessor provided an equal and opposite resistive 
force, against the lower shin. The mean force generated 
was measured in Newtons.
Quality of life: Minnesota Living with Heart Failure Questionnaire
The Minnesota Living with Heart Failure question-
naire (MLHFQ) is a disease validated questionnaire,22 
that has been extensively used in heart failure studies. 
Questionnaire scores range from 0 to 105, with higher 
scores reflecting lower quality of life. Participants were 
asked to answer each question based on their perception 
of health in the week previous to testing.
Physical activity levels
Physical activity levels were measured by the Bodymedia© 
SenseWear Pro3 Armband. The multiplane accelerom-
eter was worn continuously for the 7 days prior to testing 
to determine total energy expenditure per 24 hours 
period was used as the main indicator of physical activity.
LF-EMS acceptability questionnaire
At the end of the trial, participants were given a brief ques-
tionnaire used in previous LF-EMS studies,13 14 to collect 
feedback on the acceptability of using LF-EMS regularly. 
Questions used the Likert scale to discern cognitive and 
affective components of attitudes23 about ease of use, 
comfort, tolerability and overall satisfaction.
Safety: blood test
Venous blood samples were taken at baseline, 4 weeks 
and 8 weeks to assess creatine kinase (CK), urea and elec-
trolytes. Participants would discontinue the trial if levels 
exceeded the upper limit of normal reference ranges.
Data analysis
Data analyses for the feasibility objectives of this study 
were descriptive, based on the predetermined levels 
specified above. CI (set at 95%) were calculated for all 
secondary outcome measures in both groups and paired 
two-sample t-test conducted for between group compari-
sons. Intent-to-treat analysis was employed in this study as 
is recommended for clinical trials.24
resuLts
Feasibility criteria outcomes
Recruitment
There were 171 eligible participants identified in the 
Coventry and Warwickshire area from November 2013 
to April 2015. Sixty of 171 eligible participants (35.08%) 
were recruited to the trial. Participants were randomised 
and started on the trial during this period and were 
followed up until data collection finished in August 2015. 
Participant characteristics are presented in table 1.
Retention
Twelve of the 60 participants (4 LF-EMS, eight sham) 
(20%) withdrew and did not finish the intervention 
period (see figure 1). Of these, only three found the 
intervention intolerable (one LF-EMS, two sham). 
Other reasons for dropout were: deterioration in 
health (n=6), family problems (n=2) and implantation 
of a cardioverter defibrillator (n=1). Only 22 (45%) of 
those completing the intervention period returned for 
follow-up testing at 20 weeks. Reasons for non-follow-up 
were: deterioration in health (n=9), excluded due to 
implantation of cardiac resynchronisation therapy 
device (n=2), declined to take part without further 
explanation (n=13) and could not be contacted after 
repeated attempts (n=3).
Adherence
Forty-one (85.4%) of the 48 participants (22 LF-EMS and 
19 sham) who completed the intervention period (68.3% 
of the total sample) adhered to the strict protocol for 
the majority (>70%) of the 8 weeks. Interrogation of 
the LF-EMS controllers revealed that participants in 
the LF-EMS group became more tolerant to the inter-
vention; mean stimulation intensity increased from 
57.79 mA (95% CI 51.16 to 64.42) during week 1 of the 
study to 84.86 mA (95% CI 75.44 to 94.28) by week 8, an 
improvement of 46.5%.
‘Sham’ Placebo
The sham placebo for the study appeared to be convincing 
as only 61% of participants guessed their treatment group 
correctly. The 95% CI for the proportion of participants 
guessing correctly was (46% to 74%)%) and thus not 
significantly different from 50% which would be expected 
by chance. Furthermore, participants demonstrated an 
inclination to guess that they were randomised to LF-EMS 
regardless of group allocation.
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Table 1 Baseline demographic and clinical characteristics 
of the LF-EMS and sham placebo groups
Demographics
LF-EMS 
(n=30) Sham (n=30)
  Male (n) 20 (66%) 22 (73%)
  Age (years) 66.5±7.8 66.8±13.5
  Body mass index (kg/m2) 30.1±4.9 27.8±4.8
Comorbidities
  Prev MI/PCI/CABG 17 (56%) 11 (36%)
  Diabetes 12 (40%) 10 (33%)
  COPD 9 (30%) 8 (26%)
  AF 20 (66%) 16 (53%)
  Hypertension 13 (43%) 10 (33%
  CKD 5 (16%) 13 (43%)
Clinical
  NT-pro-BNP (pg/mL) 3086±3746 2046±2545
  Creatinine (mmol/L) 108±49 113±39
  LVEF % 39±11* 22±12†
  BPsys (mm Hg) 118±16 126±17
  BPdia (mm Hg) 69±9 74±14
  NYHA III 24 (80%) 22 (73%)
  NYHA IV 6 (20%) 8 (26%)
Data presented as mean±SD or absolute number and percent.
*n=10. Ejection fraction could not be accurately assessed in all 
patients due to poor body habitus/atrial fibrillation. An experienced 
cardiac sonographer made an ‘eyeball’ assessment of poor left 
ventricular function for all other participants.
†n=5. See previous comments.
AF, atrial fibrillation; BPdia (mm Hg), diastolic blood pressure; BPsys 
(mm Hg), systolic blood pressure; CABG, coronary artery bypass 
graft surgery; CKD, chronic kidney disease; COPD, chronic 
obstructive pulmonary disease; LF-EMS, low-frequency electrical 
muscle stimulation; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; NT-pro-BNP (pg/mL),N-terminal pro B-type 
natriuretic peptide; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention.
Safety
No abnormalities were detected in CK, urea or electro-
lytes taken before, during or after the study. Likewise, no 
adverse events due to the intervention were recorded in 
either group.
Primary outcome: 6MWT
Non-significant improvements after LF-EMS (8 week time 
point) and sham groups were observed in 6 min walk 
distance (6MWD) with a mean increase from baseline of 
24 m (p=0.13) in the LF-EMS group (table 2).
Secondary outcomes
Table 2 shows the mean values of the secondary outcome 
measures at each time point. There were no significant 
differences between groups in the change from baseline 
for any of the secondary outcome variables (table 3). 
There was a non-significant improvement in quality of life 
in both groups.
Acceptability questionnaire
Participants’ responses to the LF-EMS acceptability ques-
tionnaire are summarised in table 4. The mean response 
to putting on the straps was 2 (‘quite easy’) and the overall 
mean satisfaction of participants with the intervention 
was 6 out of 10. Mean responses to comfort, sensation, 
tolerability and continued use of LF-EMS were between 3 
(medium) and 4 (quite hard/unpleasant).
sample size calculation
The point estimate from the study and the upper CI limit 
of this estimate were calculated. The upper CI limit was 
used for the sample size calculation. For detecting the 
observed difference of 13.4 m in this study a sample size 
of 240 patients per group would be required. However, 
a recent study25 suggested that the minimal clinically 
important difference for 6MWD is 36 m in patients with 
mild–moderate CHF. The clinical benefit of the effect 
size in this study should be considered before proceeding 
with a larger trial
DIscussIOn
The predetermined criteria for proceeding to a larger trial 
were achieved for dropout (20%), adherence (68.3%) 
and sham placebo efficacy (61.53% participants guessed 
correctly). However, only 35.06% of eligible patients 
were recruited, below the target of 40%. Initial outcome 
measures revealed no significant difference between 
intervention and placebo groups, although there was a 
non-significant improvement in 6MWD and quality of life 
after LF-EMS.
Feasibility outcomes
Recruitment
Percentage uptake (35.06%) of eligible patients in the 
study was below the predetermined criteria of 40%. This 
is similar to the poor uptake of conventional cardiac 
rehabilitation (CR) nationally in the UK: <40% of eligible 
patients with heart failure accessed CR in the most recent 
National Audit of Cardiac Rehabilitation.26
Retention/adherence/tolerance
One strength of this study is the good level of adher-
ence (68.3%) and retention (80%) compared with other 
clinical studies; In the Heart  Failure: A Controlled Trial 
Investigating Outcomes in Exercise training (HF-AC-
TION) trial,27 only 40% of patients in the exercise group 
(n=1159) reported adherence to recommended training 
volumes after 3 months. This may have been because 
of the ease of independent use at home of LF-EMS, in 
combination with the weekly supervised sessions with 
an exercise physiologist. The patients recruited in the 
present trial were more debilitated yet they engaged 
more with LF-EMS than those in the HF-ACTION trial,27 
suggesting that LF-EMS maybe more acceptable to this 
population than conventional exercise.
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Figure 1 Flow diagram of a single-centre blinded parallel group randomised feasibility trial of EMS versus sham placebo in 
patients with severe heart failure. LF-EMS, low-frequency electrical muscle stimulation.
The dropout at 3 months follow-up was lower than 
expected due to ill health, device implantation and 
apathy, and would be challenging to overcome in a 
larger trial. Strategies to combat dropout could include 
combining assessment with clinical patient appointments 
to ensure compliance or arranging home visits for some 
assessments.
Feedback from the acceptability questionnaires may 
also be useful in curtailing dropout in a larger trial: 
the LF-EMS group generally thought that wearing 
the straps for an hour was ‘medium’ to ‘quite hard/
unpleasant’. Continued use of a LF-EMS was deemed 
challenging also so it is possible that a reduced 
frequency of LF-EMS while still maintaining a suffi-
cient dose, for example, 3×1 hour a week may enhance 
long-term adherence.
Tolerance to the LF-EMS intervention improved 
during the study. Mean current intensity increased by 
46% from week 1 to 8. This tolerance effect is in keeping 
with an earlier study by Crognale et al13 that showed a 
20% increase in healthy active adults. The active adults 
tolerated higher absolute stimulation levels than in this 
study, both before and after habituation, suggesting that 
patients with advanced CHF are subjectively less tolerant 
to LF-EMS than a healthy population. In addition, the 
user feedback collected seems to support this view. Vivod-
tzev and colleagues28 examined factors determining 
tolerance of EMS in patients with pulmonary disease. The 
study reported that lower tolerance to EMS was associ-
ated with greater severity of condition, fat free mass and 
inflammatory response. It is possible that the same is true 
in the CHF population but more research is needed to 
confirm this.
Outcome measures
Baseline 6MWD was higher in our study sample than in 
other advanced heart failure studies.29 This may have 
been due to high variability because of a few outliers 
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Table 2 Outcome measurements: time point averages and 95%CI
Outcome Time point LF-EMS Sham
Mean 6MWD (m)
(95% CI)
Baseline
(n)
283 (237 to 328)
29
290 (243 to 337)
29
8 weeks
(n)
312 (262 to 362)
26
318 (270 to 365)
22
20 weeks
(n)
257 (173 to 342)
12
226 (126 to 325)
10
Mean leg strength (N)
(95% CI)
Baseline
(n)
234.3 (196.5 to 272.)
29
297.5 (253 to 342)
29
8 weeks
(n)
224.9 (187.5 to 262.3)
25
321 (267.8 to 374.3)
22
20 weeks
(n)
181.6 (131.7 to 231.5)
11
207.1 (148.6 to 265.7)
10
Mean QoL score
(95% CI)
Baseline
(n)
53.1 (42.7 to 63.5)
28
50 (40 to 60.1)
29
8 weeks
(n)
43.9 (34.2 to 53.5)
25
43.1 (30.9 to 55.3)
22
20 weeks
(n)
51.7 (31.6 to 71.8)
12
37.0 (16.9 to 57)
10
Mean TEE (J)
(95% CI)
Baseline
(n)
63 438 (56 170 to 70 705)
25
65 371 (59 675 to 71 067)
27
8 weeks
(n)
59 783 (51 094 to 68 471)
19
59 687 (50 630 to 68 745)
17
20 weeks
(n)
61 878 (53 345 to 70 410)
7
63 541 (55 795 to 71 287)
6
6MWD, 6 min walk distance, QoL, quality of life; TEE, total energy expenditure.
Table 3 Changes from baseline averages and 95%CI
Outcome Time point LF-EMS Sham p Value
Mean 6MWD (m)
(95% CI)
Baseline to 8 weeks
(n)
24 (9  to 40)
26
9 (−4 to 22)
22
0.1366
Baseline to 20 weeks
(n)
0 (−32 to 31)
12
−26.30 (−63 to 11)
10
0.2409
Mean leg strength (N)
(95% CI)
Baseline to 8 weeks
(n)
−9.2 (−28.9 to 10.5)
25
6.0 (−19.3 to 31.4)
22
0.3244
Baseline to 20 weeks
(n)
−43.4 (−78.7  to −8.2)
11
−74.1 (−116.3 to −31.9)
10
0.2223
Mean QoL score
(95% CI)
Baseline to 8 weeks
(n)
−7.6 (−15.5 to 0.3)
25
−4.7 (−10.5 to 1.0)
22
0.5505
Baseline to 20 weeks
(n)
1.5 (−12.5 to 15.7)
12
−14.0 (−34 to 6)
10
0.1610
Mean TEE (J)
(95% CI)
Baseline to 8 weeks
(n)
−4635 (−3963 to 4692)
19
−8168 (−14 342 to −1995)
17
0.5108
Baseline to 20 weeks
(n)
1686 (−6435 to 9809)
7
4177 (−7695 to 16 050)
6
0.6634
6MWD, 6 min walk distance; QoL, quality of life; TEE, total energy expenditure.
in each group. This reflects the subjective nature of 
the NYHA classification system. However, signs and 
symptoms of advanced heart failure were primarily 
the eligibility criteria for this study and not 6MWD. In 
addition, the ≤300 m distance cut-off (below which our 
baseline mean falls) is often cited, as prognostically 
important and reflective of advanced disease in many 
investigations.30–32 The non-significant improvements in 
exercise capacity as measured by 6 min walk were smaller 
than those in a meta-analysis of EMS in patients with 
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Table 4 Mean responses to acceptability questionnaire 
and SD
Question
Mean 
response
1. I found putting on the straps (1-easy, 
5-hard)
2.0 (±1.17)
2. At the highest intensity I found 
the comfort level (1-acceptable, 
5-unacceptable)
3.5 (±1.19)
3. Overall I found the sensation 
(1-pleasant, 5-unpleasant)
3.3 (±1.13)
4. I found putting on the LF-EMS for an 
hour (1-easy, 5-hard)
3.1 (±1.08)
5. I think I would find staying on a LF-
EMS training routine (1-easy, 5-hard)
3.4 (±1.29)
6. Overall satisfaction with LF-EMS 
as a way of improving your fitness (1-
none,10 extremely satisfied)
6.0 (±1.94)
LF-EMS, low-frequency electrical muscle stimulation.
heart failure by Smart et al.10 These authors reported a 
combined improvement in 6MWD of 46.9 m versus usual 
care or placebo, compared with the effect size of 13.2 m 
in this study. However, patients in this study were more 
symptomatic than those included in the meta-analysis,10 
and thus had a lower baseline exercise capacity (286 m 
vs 342 m). Nevertheless, the mean relative increase (5%) 
in walk distance of participants in the LF-EMS group is 
within the measurement error associated with this test33 
and probably should not be considered clinically signifi-
cant.25 The extrapolation from these results that patients 
with severe CHF are beyond help from EMS maybe 
premature; a longer training period maybe required to 
show meaningful changes in exercise capacity, partic-
ularly as some participants took longer to tolerate 
meaningful EMS intensities than others.
Quality of life (MLHFQ) improved in both groups 
after the intervention. This may, in part, relate to the 
psychosocial benefits of engaging with researchers 
regularly in the cardiac rehabilitation facility.34 The 
placebo effect of both interventions and its influence 
on patients’ perception of well-being should not be 
underestimated.
Based on previous research by Banerjee et al,15 16 and 
numerous high-frequency EMS studies,12 35 36 improve-
ment in leg strength after use of LF-EMS was expected. 
The current trial however showed no significant change 
in muscle strength. Muscle wasting, prevalent in many 
patients with advanced heart failure,37 could explain 
this observation. The chronic impairment of muscle 
tissue caused by heart failure affects the muscle and skin 
nerve receptors and hence contractility of the weakened 
muscle.38 Participants with more functional leg muscles 
therefore may have received greater stimulus to muscle 
tissue that others did for the same level of current inten-
sity. This suggests that LF-EMS may not be effective for all 
patients with advanced CHF.
Limitations
The sample for this study was small as is recommended 
for feasibility studies19 and this limits the external validity 
of our findings. Participants were deemed eligible for the 
study based on the judgement of experienced heart failure 
clinicians using available knowledge. This may have led to 
greater variability in disease severity/limitation than was 
intended. The current amplitude (mA) stimulus intensity 
that participants chose to use was a limitation to the study 
design. Participants were instructed to adhere to the 
‘maximum tolerable intensity’ during LF-EMS sessions. 
Due to considerable individual differences in the subjec-
tive perception of discomfort associated with EMS, it is 
therefore likely that there was variability in the intensity 
that individuals received.
cOncLusIOn
As some of the predetermined feasibility criteria were 
met in this trial, a larger study into the effects of LF-EMS 
on patients with advanced heart failure could be under-
taken. However, this ‘difficult to engage with’ patient 
group would be very challenging to recruit and follow-up 
in sufficient numbers to provide definitive data on its effi-
cacy. The improvements seen in this study in 6MWD, and 
quality of life measures, were not statistically significant. 
Leg strength and physical activity levels showed no signif-
icant change. An intervention period >8 weeks could be 
considered to give participants more time to adjust to the 
intervention. More investigation is required to determine 
which patients with CHF are unresponsive to LF-EMS due 
to severe muscle dysfunction.
A larger trial may be feasible with this difficult popu-
lation: however, it is unlikely that the non-significant 
improvement in exercise capacity and quality of life 
found in this pilot study justifies a larger pragmatic trial.
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